Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | 5Ca.3O4P.HO |
| Molecular Weight | 502.311 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[OH-].[Ca++].[Ca++].[Ca++].[Ca++].[Ca++].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O
InChI
InChIKey=XYJRXVWERLGGKC-UHFFFAOYSA-D
InChI=1S/5Ca.3H3O4P.H2O/c;;;;;3*1-5(2,3)4;/h;;;;;3*(H3,1,2,3,4);1H2/q5*+2;;;;/p-10
| Molecular Formula | Ca |
| Molecular Weight | 40.078 |
| Charge | 2 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | HO |
| Molecular Weight | 17.0073 |
| Charge | -1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | O4P |
| Molecular Weight | 94.9714 |
| Charge | -3 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: https://www.drugs.com/inactive/calcium-phosphate-dibasic-anhydrous-463.htmlhttp://apps.who.int/iris/bitstream/10665/43579/1/9789241530729_eng.pdfhttp://www.globalrph.com/calcium_supplements.htm | https://www.ncbi.nlm.nih.gov/pubmed/26265479Curator's Comment: description was created based on several sources, including
https://www.alfa.com/en/catalog/043674/
Sources: https://www.drugs.com/inactive/calcium-phosphate-dibasic-anhydrous-463.htmlhttp://apps.who.int/iris/bitstream/10665/43579/1/9789241530729_eng.pdfhttp://www.globalrph.com/calcium_supplements.htm | https://www.ncbi.nlm.nih.gov/pubmed/26265479
Curator's Comment: description was created based on several sources, including
https://www.alfa.com/en/catalog/043674/
Calcium lactate is the salt that consists of two lactate anions for each calcium cation (Ca2+); this salt is used as a calcium supplement to treat hypocalcemia. However, as a source of free calcium, this salt is less convenient than calcium citrate. Calcium lactate inhalation powder also called as PUR118 participated in phase I clinical trials to determine whether this formulation was safe and tolerable in a population of subjects with Cystic Fibrosis (CF). PUR118 also was used in another clinical trials to evaluate its effect on ozone-induced airway Inflammation in healthy normal volunteers in case of Chronic Obstructive Pulmonary Disease (COPD). The obtained results revealed that PUR118 reduced the severity of acute exacerbations in COPD and CF and had the beneficial impacts on mortality, morbidity, and quality of life in affected individuals. However, both studies were discontinued.
Originator
Approval Year
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Palliative | Unknown Approved UseUnknown |
|||
| Palliative | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseHypocalcemia, chronic (treatment) — Oral calcium supplements provide a source of calcium ion for treating calcium depletion occurring in conditions such as chronic hypoparathyroidism, pseudohypoparathyroidism, osteomalacia, rickets, chronic renal failure, and hypocalcemia secondary to the administration of anticonvulsant medications. When chronic hypocalcemia is due to vitamin D deficiency, oral calcium salts may be administered concomitantly with vitamin D analogs. However, calcium phosphate should not be used in patients with hypoparathyroidism or renal failure, since phosphate levels may be too high and giving more phosphate would exacerbate the condition. Calcium supplements should not be used in hyperparathyroidism, unless the need for a calcium supplement is high and the patient is carefully monitored. For treatment of hypocalcemia, supplementation is preferred |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Studies on the calcemic effect of intravenous secretin in humans. | 1975 Jun |
|
| [Early stage of cardiomyopathy: mechanisms of damage and compensation]. | 1999 Jul |
|
| Transient kinetic analysis of the 130-kDa myosin I (MYR-1 gene product) from rat liver. A myosin I designed for maintenance of tension? | 1999 Jul 30 |
|
| Modifications induced by LDL from type 1 diabetic patients on endothelial cells obtained from human umbilical vein. | 1999 Nov |
|
| Effects of a calcium receptor activator on the cellular response to calcium in human keratinocytes. | 1999 Sep |
|
| Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor. | 1999 Sep |
|
| Discovery of CP-199,330 and CP-199,331: two potent and orally efficacious cysteinyl LT1 receptor antagonists devoid of liver toxicity. | 1999 Sep 20 |
|
| Regulation of Na/K-ATPase beta1-subunit gene expression by ouabain and other hypertrophic stimuli in neonatal rat cardiac myocytes. | 2000 Dec |
|
| Molecular cloning and characterization of a second human cysteinyl leukotriene receptor: discovery of a subtype selective agonist. | 2000 Dec |
|
| Neuropeptide Y (NPY) potentiates phenylephrine-induced mitogen-activated protein kinase activation in primary cardiomyocytes via NPY Y5 receptors. | 2000 Feb 15 |
|
| Vanadate induces calcium signaling, Ca2+ release-activated Ca2+ channel activation, and gene expression in T lymphocytes and RBL-2H3 mast cells via thiol oxidation. | 2000 Jan 15 |
|
| Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells. | 2000 Jan 7 |
|
| NAIP interacts with hippocalcin and protects neurons against calcium-induced cell death through caspase-3-dependent and -independent pathways. | 2000 Jul 17 |
|
| A family of gamma-like calcium channel subunits. | 2000 Mar 24 |
|
| Effects of a calcimimetic compound and naturally activating mutations on the human Ca2+ receptor and on Ca2+ receptor/metabotropic glutamate chimeric receptors. | 2000 Nov |
|
| Inhibition of proteolysis by a cyclooxygenase inhibitor, indomethacin. | 2000 Nov |
|
| Mechanism of extracellular calcium regulation of intestinal epithelial tight junction permeability: role of cytoskeletal involvement. | 2000 Oct 15 |
|
| Pilocarpine-induced status epilepticus causes N-methyl-D-aspartate receptor-dependent inhibition of microsomal Mg(2+)/Ca(2+) ATPase-mediated Ca(2+) uptake. | 2000 Sep |
|
| Characterization of the human cysteinyl leukotriene 2 receptor. | 2000 Sep 29 |
|
| Ca2+-induced contraction of cat esophageal circular smooth muscle cells. | 2001 Apr |
|
| Expression and functional analysis of chemokine receptors in human peripheral blood leukocyte populations. | 2001 Apr 7 |
|
| Endothelin-induced changes of secondary messengers in cultured corneal endothelial cells. | 2001 Aug |
|
| The transient receptor potential protein homologue TRP6 is the essential component of vascular alpha(1)-adrenoceptor-activated Ca(2+)-permeable cation channel. | 2001 Feb 16 |
|
| Molecular and functional characterization of a family of rat brain T-type calcium channels. | 2001 Feb 9 |
|
| Extracellular calcium-sensing receptor is expressed in rat hepatocytes. coupling to intracellular calcium mobilization and stimulation of bile flow. | 2001 Feb 9 |
|
| Aluminum toxicity alters the regulation of calbindin-D28k protein and mRNA expression in chick intestine. | 2001 Jul |
|
| Endothelin- and sarafotoxin-induced receptor-mediated calcium mobilization in a clonal murine osteoblast-like cell line, MC3T3-E1/B. | 2001 Jun |
|
| Mechanisms of regulation of agonist efficacy at the 5-HT(1A) receptor by phospholipid-derived signaling components. | 2001 Jun |
|
| Vasopressin-stimulated Ca2+ spiking in vascular smooth muscle cells involves phospholipase D. | 2001 Jun |
|
| Histamine induces exocytosis and IL-6 production from human lung macrophages through interaction with H1 receptors. | 2001 Mar 15 |
|
| Regression of ventral striatum hypometabolism after calcium/calcitriol therapy in paroxysmal kinesigenic choreoathetosis due to idiopathic primary hypoparathyroidism. | 2001 Nov |
|
| Hypoxia-induced regulation of MAPK phosphatase-1 as identified by subtractive suppression hybridization and cDNA microarray analysis. | 2001 Nov 30 |
|
| Phosphoinositide 3-kinase isoforms selectively couple receptors to vascular L-type Ca(2+) channels. | 2001 Oct 12 |
|
| Replacement of the muscle-specific sarcoplasmic reticulum Ca(2+)-ATPase isoform SERCA2a by the nonmuscle SERCA2b homologue causes mild concentric hypertrophy and impairs contraction-relaxation of the heart. | 2001 Oct 26 |
|
| Ameliorative effect of vasopressin-(4-9) through vasopressin V(1A) receptor on scopolamine-induced impairments of rat spatial memory in the eight-arm radial maze. | 2001 Sep 7 |
|
| Cannabinoids attenuate depolarization-dependent Ca2+ influx in intermediate-size primary afferent neurons of adult rats. | 2002 |
|
| The role of endogenous human Trp4 in regulating carbachol-induced calcium oscillations in HEK-293 cells. | 2002 Apr 19 |
|
| Interaction of intravenous anesthetics with recombinant human M1-M3 muscarinic receptors expressed in chinese hamster ovary cells. | 2002 Dec |
|
| Characterization of basolateral K+ channels underlying anion secretion in the human airway cell line Calu-3. | 2002 Feb 1 |
|
| Characterization of the bone-resorptive effect of interleukin-11 in cultured mouse calvarial bones. | 2002 Jul |
|
| Delayed asystolic cardiac arrest after diltiazem overdose; resuscitation with high dose intravenous calcium. | 2002 Jul |
|
| Expression of functional CCR and CXCR chemokine receptors in podocytes. | 2002 Jun 15 |
|
| Investigation of a functional requirement for isoprenylation by the human prostacyclin receptor. | 2002 Mar |
|
| Diacylglycerol activates the influx of extracellular cations in T-lymphocytes independently of intracellular calcium-store depletion and possibly involving endogenous TRP6 gene products. | 2002 May 15 |
|
| Neuronal apoptosis inhibitory protein: Structural requirements for hippocalcin binding and effects on survival of NGF-dependent sympathetic neurons. | 2002 Nov 4 |
|
| Mechanism of enhanced calcium sensitivity and alpha 2-AR vasoreactivity in chronic NOS inhibition hypertension. | 2003 Jan |
|
| Dietary calcium source influences body composition, glucose metabolism and hormone levels in a mouse model of postmenopausal obesity. | 2009 Jul-Aug |
|
| A combination of calcium phosphate and probiotics beneficially influences intestinal lactobacilli and cholesterol metabolism in humans. | 2012 Apr |
|
| Long-term remineralizing effect of casein phosphopeptide-amorphous calcium phosphate (CPP-ACP) on early caries lesions in vivo: a systematic review. | 2014 Jul |
|
| Dietary interventions for mineral and bone disorder in people with chronic kidney disease. | 2015 Sep 16 |
Sample Use Guides
Proper administration of calcium carbonate or phosphate: Taking tablets 1 to 11/2 hours after meals, unless otherwise directed by physician. Recommended doses for adolescents and adults is 800-1200 mg/day; for pregnat orbreast-feeding females 1200 mg/day.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:13:48 GMT 2025
by
admin
on
Mon Mar 31 18:13:48 GMT 2025
|
| Record UNII |
91D9GV0Z28
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Preferred Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
LOINC |
81622-3
Created by
admin on Mon Mar 31 18:13:48 GMT 2025 , Edited by admin on Mon Mar 31 18:13:48 GMT 2025
|
||
|
LOINC |
87480-0
Created by
admin on Mon Mar 31 18:13:48 GMT 2025 , Edited by admin on Mon Mar 31 18:13:48 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
CHEMBL2218916
Created by
admin on Mon Mar 31 18:13:48 GMT 2025 , Edited by admin on Mon Mar 31 18:13:48 GMT 2025
|
PRIMARY | |||
|
CHEMBL2106566
Created by
admin on Mon Mar 31 18:13:48 GMT 2025 , Edited by admin on Mon Mar 31 18:13:48 GMT 2025
|
PRIMARY | |||
|
1306-06-5
Created by
admin on Mon Mar 31 18:13:48 GMT 2025 , Edited by admin on Mon Mar 31 18:13:48 GMT 2025
|
PRIMARY | |||
|
215-145-7
Created by
admin on Mon Mar 31 18:13:48 GMT 2025 , Edited by admin on Mon Mar 31 18:13:48 GMT 2025
|
NON-SPECIFIC STOICHIOMETRY | |||
|
SUB01847MIG
Created by
admin on Mon Mar 31 18:13:48 GMT 2025 , Edited by admin on Mon Mar 31 18:13:48 GMT 2025
|
PRIMARY | |||
|
TRIBASIC CALCIUM PHOSPHATE
Created by
admin on Mon Mar 31 18:13:48 GMT 2025 , Edited by admin on Mon Mar 31 18:13:48 GMT 2025
|
PRIMARY | Description: A white, amorphous powder; odourless or almost odourless. Solubility: Practically insoluble in water and ethanol (~750 g/l) TS; soluble in hydrochloric acid (~70 g/l) TS and nitric acid (~130 g/l) TS. Category: Tablet diluent. Storage: Calcium phosphate should be kept in a well-closed container. Additional information: At relative humidities between 15% and 65%, the equilibrium moisture content at 25 ?C is about 2%, but at relative humidities above 75% small additional amounts of moisture are absorbed. Definition: Calcium phosphate is a mixture consisting mainly of Ca3(PO4)2 together with CaHPO4. Calcium phosphate contains not less than 34.0% and not more than the equivalent of 40.0% of calcium, Ca, calculated with reference to the ignited substance. | ||
|
C45678
Created by
admin on Mon Mar 31 18:13:48 GMT 2025 , Edited by admin on Mon Mar 31 18:13:48 GMT 2025
|
CONCEPT | Industrial Aid | ||
|
91D9GV0Z28
Created by
admin on Mon Mar 31 18:13:48 GMT 2025 , Edited by admin on Mon Mar 31 18:13:48 GMT 2025
|
PRIMARY | |||
|
m4784
Created by
admin on Mon Mar 31 18:13:48 GMT 2025 , Edited by admin on Mon Mar 31 18:13:48 GMT 2025
|
PRIMARY | Merck Index | ||
|
5804
Created by
admin on Mon Mar 31 18:13:48 GMT 2025 , Edited by admin on Mon Mar 31 18:13:48 GMT 2025
|
PRIMARY | |||
|
100000138411
Created by
admin on Mon Mar 31 18:13:48 GMT 2025 , Edited by admin on Mon Mar 31 18:13:48 GMT 2025
|
PRIMARY | |||
|
Calcium hydroxyphosphate
Created by
admin on Mon Mar 31 18:13:48 GMT 2025 , Edited by admin on Mon Mar 31 18:13:48 GMT 2025
|
PRIMARY | |||
|
SUB34727
Created by
admin on Mon Mar 31 18:13:48 GMT 2025 , Edited by admin on Mon Mar 31 18:13:48 GMT 2025
|
PRIMARY | |||
|
52254
Created by
admin on Mon Mar 31 18:13:48 GMT 2025 , Edited by admin on Mon Mar 31 18:13:48 GMT 2025
|
PRIMARY | |||
|
SUB77913
Created by
admin on Mon Mar 31 18:13:48 GMT 2025 , Edited by admin on Mon Mar 31 18:13:48 GMT 2025
|
PRIMARY | |||
|
D017886
Created by
admin on Mon Mar 31 18:13:48 GMT 2025 , Edited by admin on Mon Mar 31 18:13:48 GMT 2025
|
PRIMARY | |||
|
DBSALT002431
Created by
admin on Mon Mar 31 18:13:48 GMT 2025 , Edited by admin on Mon Mar 31 18:13:48 GMT 2025
|
PRIMARY | |||
|
235-330-6
Created by
admin on Mon Mar 31 18:13:48 GMT 2025 , Edited by admin on Mon Mar 31 18:13:48 GMT 2025
|
PRIMARY | |||
|
1087031
Created by
admin on Mon Mar 31 18:13:48 GMT 2025 , Edited by admin on Mon Mar 31 18:13:48 GMT 2025
|
PRIMARY | |||
|
SUB13191MIG
Created by
admin on Mon Mar 31 18:13:48 GMT 2025 , Edited by admin on Mon Mar 31 18:13:48 GMT 2025
|
PRIMARY | |||
|
C84224
Created by
admin on Mon Mar 31 18:13:48 GMT 2025 , Edited by admin on Mon Mar 31 18:13:48 GMT 2025
|
PRIMARY | |||
|
91D9GV0Z28
Created by
admin on Mon Mar 31 18:13:48 GMT 2025 , Edited by admin on Mon Mar 31 18:13:48 GMT 2025
|
PRIMARY | |||
|
14781
Created by
admin on Mon Mar 31 18:13:48 GMT 2025 , Edited by admin on Mon Mar 31 18:13:48 GMT 2025
|
PRIMARY | |||
|
9679
Created by
admin on Mon Mar 31 18:13:48 GMT 2025 , Edited by admin on Mon Mar 31 18:13:48 GMT 2025
|
PRIMARY | |||
|
49334
Created by
admin on Mon Mar 31 18:13:48 GMT 2025 , Edited by admin on Mon Mar 31 18:13:48 GMT 2025
|
PRIMARY | RxNorm |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
